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Sexual transmission of Ebola virus (EBOV) has been demonstrated more than a year after recovery from
the acute phase of Ebola virus disease (EVD). The mechanisms underlying EBOV persistence and sexual
transmission are not currently understood. Using the acute macaque model of EVD, we hypothesized
EBOV would infect the reproductive tissues and sought to localize the infection in these tissues using
immunohistochemistry and transmission electron microscopy. In four female and eight male macaques
that succumbed to EVD between 6 and 9 days after EBOV challenge, we demonstrate widespread EBOV
infection of the interstitial tissues and endothelium in the ovary, uterus, testis, seminal vesicle,
epididymis, and prostate gland, with minimal associated tissue immune response or organ pathology.
Given the widespread involvement of EBOV in the reproductive tracts of both male and female
macaques, it is reasonable to surmise that our understanding of the mechanisms underlying sexual
transmission of EVD and persistence of EBOV in immune-privileged sites would be facilitated by the
development of a nonhuman primate model in which the macaques survived past the acute stage into
convalescence. (Am J Pathol 2018, 188: 550e558; https://doi.org/10.1016/j.ajpath.2017.11.004)

Sexual transmission of ﬁloviruses has been suspected for as
long as these viruses have been recognized as human
pathogens. During the ﬁrst recorded outbreak of Marburg
virus disease in 1967, sexual transmission from an infected
man to a woman was presumed but never proved.1 Ebola
virus (EBOV) was detected in the semen of a researcher
infected while handling diagnostic samples from the ﬁrst
recorded EBOV outbreak in 1976.2 The 2014 to 2016
EBOV outbreak in West Africa again raised the question of
sexual transmission of ﬁloviruses and the potential for
asymptomatic infections and EBOV persistence in immuneprivileged sites.3e6 Findings from >17,000 survivors of the
outbreak in West Africa suggest sexual transmission is rare.
To date, only two recorded incidences of sexual transmission of EBOV from that outbreak have been documented.7,8 However, the implications of EBOV
transmission by this route are signiﬁcant given an Ebola

virus disease (EVD) mortality rate of >40%.9,10 We
hypothesized that EBOV would infect the reproductive
tissues in the macaque model of acute EVD. The purpose of
this study was to identify and localize the virus within the
reproductive tissues in the macaque model, typically acutely
fatal between 6 and 10 days after i.m. challenge. Using this
EVD model, we demonstrate EBOV infection of the
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Ebola in the Macaque Reproductive Tract
Table 1

Signalment, EBOV in Peripheral Blood, and EBOV Distribution in the Reproductive Tract of Female and Male Macaques

Animal Macaque
ID
species

EBOV IHC results
Necropsy
EBOV vRNA,
after
inoculation, copy/mL
Age,
Ovary
Uterus
(log10)
months days

1

Cynomolgus 46

7

10.6

2

Cynomolgus 53

8

9.96

3

Cynomolgus 53

7

10.1

4

Rhesus

35

7

10.4

5

Cynomolgus 48

6

10.3

6

Cynomolgus 44

8

10

7

Rhesus

44

9

8.83

8

Rhesus

48

7

9.78

9

Rhesus

58

8

9.95

10

Rhesus

56

7

10.2

11

Rhesus

35

7

10.1

12

Rhesus

38

6

10.6

Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular

Testis

Prostate
gland

Seminal
vesicle

Epididymis TEM results

Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular

Stromal/EC
Stromal
Stromal/EC
Stromal
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular

Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular

Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular
Stromal/
vascular

Stromal/ Stromal/EC
vascular
Stromal/ Stromal/EC
vascular
NP
Stromal/EC
NP

Stromal/EC

Stromal/ Stromal/EC
vascular
Stromal/ Stromal/EC
vascular
Stromal/ Stromal/EC
vascular
Stromal/
NP
vascular

EBOV, Ebola virus; EC, endothelial cell; ID, identiﬁcation; IHC, immunohistochemistry; NP, not performed; TEM, transmission electron microscopy; vRNA,
viral RNA.

interstitial or supporting connective tissues of the male and
female reproductive organs, with minimal associated tissue
immune response or organ pathology.
Twelve macaques, seven rhesus (Macaca mulatta; one
female and six males) and ﬁve cynomolgus (Macaca fascicularis; three females and two males), ranging in age from
35 to 58 months, were challenged with 1000 plaque-forming
units i.m. of EBOV Makona C05.11 Macaques were
euthanized after meeting end point criteria between 6 and 9
days after EBOV challenge. Each macaque underwent a
complete postmortem examination when predetermined end
point criteria12 for EVD were reached. Reproductive tissues
were collected from all macaques for routine histology,
immunohistochemistry (IHC) for EBOV viral protein 40
(VP40) matrix protein and/or glycoprotein (GP), and
transmission electron microscopy examination.13 Immunohistochemistry for EBOV VP40 and/or GP was positive in
the reproductive organs of all 12 macaques. Transmission
electron microscopy of the reproductive tissues was performed in 11 of 12 macaques that succumbed to EVD, and
widespread EBOV infection of the stromal connective tissues, including endothelial cells, was observed in all macaques examined. A summation of ﬁndings can be found in
Table 1.
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Materials and Methods
Animal Ethics Statement
This study was performed in strict adherence to the Guide for
the Care and Use of Laboratory Animals14 of the NIH, the
Ofﬁce of Animal Welfare, and the US Department of Agriculture. All work was approved by the US National Institute of
Allergy and Infectious Diseases, Division of Clinical Research
Animal Care and Use Committee, and performed at the US
National Institute of Allergy and Infectious Diseases Research
Facilities. Procedures were performed after animals had been
anesthetized by trained personnel under the supervision of
veterinary staff. Food and water were available ad libitum.

Animals
This study includes 12 macaques that served as controls in
three separate studies that were designed to evaluate the
efﬁcacy of a therapeutic agent intended to protect against the
development of EVD. The ﬁrst two experiments are
described by Johnson et al.15 The seven rhesus macaques
(M. mulatta) and ﬁve cynomolgus macaques (M.
fascicularis) ranged in age from 35 to 58 months, with a
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total of four females (three cynomolgus and one rhesus) and
eight males (two cynomolgus and six rhesus). These 12
macaques were randomized to control groups before EBOV
i.m. challenge with EBOV (Zaire species) in the lateral head
of the right triceps muscle using the Makona C05 EBOV
isolate at a target dose of 1000 plaque-forming units.11 All
macaques succumbed to EVD between 6 and 9 days after
EBOV challenge.

viruseinfected liver from an EBOV-infected macaque and
liver from an EBOV-naïve macaque, as positive and negative
controls, respectively. In addition, assay controls (omission of
the primary antibody) and isotype controls were performed for
EBOV-VP40 (mouse IgG1; catalog number ab18443; Abcam,
Cambridge, MA) and EBOV-GP (rabbit IgG; catalog number
ab27478; Abcam). The distribution of EBOV IHC staining in
the reproductive tissues was similar with anti-EBOV VP40 and
anti-EBOV GP.

Blood Collection
Electron Microscopy
Nine pre-EBOV challenge blood draws were performed in
each macaque, the last at 15 days before EBOV challenge (0
day). After EBOV challenge, blood draws were performed
every other day starting at 2 days until 8 days after EBOV
challenge. The last blood draw was performed immediately
before necropsy. Complete blood cell counts, select serum
chemistries, and real-time quantitative PCR for viremia
were performed on these samples.

Viremia by Quantitative RT-PCR
Whole blood was inactivated in TRIzol LS (Thermo Fisher
Scientiﬁc, Waltham, MA) in accordance with established
methods for inactivation of risk group 4 pathogens. Brieﬂy,
total RNA was isolated using the QIAamp Viral RNA Mini Kit
(Qiagen, Germantown, MD) using 700 mL of TRIzol LS
inactivated sample that was added to 280 mL of Qiagen Buffer
AVL containing carrier RNA. The sample was eluted in 70 mL
of Buffer AVE, aliquoted, and frozen until assayed. Whole
blood viral load was measured using BEI Resources Critical
Reagents Program (Manassas, VA) EZ1 quantitative RT-PCR
kit assay, in accordance with manufacturer’s instructions, and
reported as viral RNA copies (log10) per mL of sample.

Tissue Processing and Immunohistochemistry
Reproductive tissue collected from females (uterus and
ovaries) and males (testes, prostate, seminal vesicles, head, and
tail of the epididymides) at necropsy was ﬁxed in 10% neutralbuffered formalin in preparation for routine histopathology and
immunohistochemistry. Ebola virus immunohistochemistry
was performed on routinely processed tissue with an
anti-EBOV VP40 (catalog number 0201-016; IBT
Bioservices, Rockville, MD) or anti-EBOV GP antibody
(catalog number 0301-015; IBT Bioservices), followed by a
biotinylated anti-mouse (catalog number 115-065-166; Jackson Immunoresearch Laboratories, Westgrove, PA; for VP40)
or anti-rabbit (catalog number 111-065-144; Jackson Immunoresearch Laboratories; for GP) secondary antibody and an
avidin-biotin peroxidase tertiary antibody (catalog number
PK-6100; Vector Laboratories, Burlingame, CA). Ebola virus
was visualized with 3,30 -diaminobenzidine chromogen (catalog number BDB2004L; Biocare, Pacheco, CA), counterstained with hematoxylin, and assessed by a single pathologist
(D.L.P.). Immunohistochemical controls included Ebola
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For conventional thin-section microscopic evaluation, tissues
were ﬁxed for 72 hours in 2.5% glutaraldehyde and 2.0%
paraformaldehyde (E.M. Sciences, Warrington, PA) in
Millonig’s sodium phosphate buffer (Tousimis Research,
Rockville, MD). Fixed tissues were washed repeatedly in
Millonig’s buffer and then incubated for 2 hours in 1.0%
osmium tetroxide. After rinsing steps in ultrapure water and en
bloc staining with 2.0% uranyl acetate, tissues were dehydrated
in a series of graded ethanols and inﬁltrated and embedded in
Spurr’s plastic resin (E.M. Sciences). Embedded blocks were
divided into sections using a Leica UC7 ultramicrotome
(Leica, Wetzlar, Germany). Sections (70 to 80 nm thick) were
collected on 200 mesh copper grids and poststained with
Reynold’s lead citrate. Samples were examined in an FEI
Tecnai Spirit Twin transmission electron microscope (FEI
Company, Hillsboro, OR), operating at 80 kV.

Results
Ebola Virus Infects Mesenchymal Cells in the Ovary
Histopathological lesions in the ovary secondary to EVD were
not observed in the macaques examined. Inclusion bodies
could be seen in the mesenchymal thecal cells surrounding
secondary and tertiary ovarian follicles. Immunohistochemical
staining for EBOV GP in the ovary was multifocally positive in
the thecal cells surrounding secondary and tertiary ovarian
follicles and in the vascular endothelium in macaques that
succumbed to EVD (Figure 1). Immunohistochemical positivity in the granulosa cells was rare. Ultrastructural examination of the ovary conﬁrmed viral infection of ovarian stromal
cells and endothelial cells (Figure 1). Fimbrial epithelial cells
of the salpinx (Fallopian tube or oviduct) stained positive
multifocally for EBOV VP40 and GP (data not shown).

Ebola Virus Infects the Endometrial Stromal Cells and
Smooth Muscle Cells of the Myometrium
Histopathological lesions in the uterus secondary to EVD
were not observed in the macaques examined. Immunohistochemical staining for EBOV VP40 revealed widespread
positivity in the vasculature, endometrial stromal cells, and
smooth muscle cells of the myometrium in macaques that
succumbed to EVD (Figure 1). Ultrastructural examination

ajp.amjpathol.org

-

The American Journal of Pathology

Ebola in the Macaque Reproductive Tract

Figure 1 Ovary (A, C, and E) and uterus (B, D,
and F). A: Section of ovary from a macaque 7 days
after Ebola virus (EBOV) challenge immunohistochemically (IHC) stained for EBOV glycoprotein
(GP) shows positive cytoplasmic staining (brown)
of the stroma, most prominent around secondary
and tertiary ovarian follicles, consistent with the
theca interna layer. B: Section of uterus IHC
stained for EBOV viral protein 40 (VP40) matrix
protein shows extensive positive cytoplasmic
staining (brown) within the endometrial stroma,
vasculature, and smooth muscle of the myometrium. C and E: The black boxed area from A shows
the anatomical orientation of the transmission
electron micrographs (TEMs). C: An intracytoplasmic EBOV inclusion body (red boxed area)
forming nucleocapsid structures is present in a
mesenchymal cell in the ovary adjacent to a
granulosa cell layer (GC; left). Extracellular, ﬁlamentous, mature EBOV particles are in the interstitium (white arrows). The white arrowheads
point to additional intracytoplasmic EBOV inclusion bodies in ovarian mesenchymal cells. E:
Higher magniﬁcation of the inclusion body in the
red boxed area in C. An intracytoplasmic inclusion
body forming EBOV nucleocapsid structures. White
arrows point to mature EBOV particles free within
the interstitial space. D and F: The black boxed
area in B represents the anatomical orientation of
smooth muscle cells seen in TEMs. D: An intracytoplasmic EBOV inclusion body (red boxed area)
is present in a smooth muscle cell of the myometrium. Adjacent to the smooth muscle cells are
mature ﬁlamentous EBOV particles free within the
interstitial space. F: Higher magniﬁcation of the
red boxed area in D. Intracytoplasmic EBOV inclusion body (black arrowhead) forming nucleocapsid structures within a smooth muscle cell in
the myometrium. Adjacent to the smooth muscle
cells are ﬁlamentous mature EBOV particles free
within interstitial space (black arrows). Scale
bars: 500 mm (A and B); 2 mm (C and D); 500 nm
(E and F).

of the uterus conﬁrmed viral infection of endometrial stromal
cells and smooth muscles cells of the myometrium (Figure 1).

Ebola Virus Infects Interstitial Mesenchymal Cells in
the Testis
Histopathological lesions in the testis were uncommon but
included the presence of spermatid giant cells and oligospermia; however, macaque species are seasonal breeders
and sperm density must be interpreted in the context of age,
social rank, recent changes in social housing,16 and
photoperiod or season.17 Uncommonly, thrombosis with
infarction of testicular stroma occurred secondary to
EVD-induced coagulopathy, resulting in areas of ischemic
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necrosis of the testicular tissue. Immunohistochemistry for
EBOV VP40 and GP in the testis revealed widespread
positivity in the interstitial connective tissues, including
endothelial cells (Figure 2). Ultrastructural examination of
the testis conﬁrmed viral infection of interstitial connective
tissues, including endothelial cells (Figure 2).

Ebola Virus Infects Interstitial Mesenchymal Cells in
the Accessory Male Sex Glands (Prostate Gland,
Seminal Vesicle, and Epididymis)
In the prostate gland and seminal vesicle, histopathological
lesions secondary to EVD were not observed, despite widespread immunohistochemical positivity for EBOV VP40 and
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Figure 2 Testis (A, C, and E) and prostate
gland (B, D, and F). A: Immunohistochemistry
(IHC) for Ebola virus (EBOV) glycoprotein (GP)
shows positive cytoplasmic staining (brown)
within the interstitium of the testis. The spermatogonia and Sertoli cells of the seminiferous
tubules are negative for EBOV GP. B: Section of
prostate gland IHC stained for EBOV viral protein
40 (VP40) matrix protein shows multifocal positive
cytoplasmic staining (brown) of the interstitial
mesenchymal cells. C and E: The black boxed area
in A represents the anatomical orientation of the
transmission electron micrographic (TEM) images.
C: Intracytoplasmic EBOV inclusion bodies can be
seen within mesenchymal cells (red boxed area)
and endothelial cells (black arrowhead) within
the testicular interstitium adjacent to an intact
seminiferous tubule (ST; left) in a macaque 6 days
after EBOV challenge. The endothelial cells of the
capillary (Cap) are multifocally electron lucent
(edema). The capillary lumen contains ﬁbrin (F). E:
Higher magniﬁcation of the red boxed area in C.
EBOV nucleocapsid formation can be seen within
an intracytoplasmic inclusion body (center) present within an interstitial mesenchymal cell of the
testis seen in C. Adjacent to this inclusion body
are mature EBOV particles free within the interstitial space (black arrows). D and F: The black
boxed area in B represents the anatomical orientation of the image seen in TEMs. D: Filamentous
EBOV particles are present within a disrupted and
expanded smooth endoplasmic reticulum (ER) of
an interstitial mesenchymal cell. An EBOV intracytoplasmic inclusion body is present adjacent to
the expanded ER (white circle). F: Higher magniﬁcation of the red boxed area in D, demonstrating
ﬁlamentous EBOV particles (black arrows) among
expanded ER membranes. Scale bars: 200 mm
(A and B); 2 mm (C); 1 mm (D); 500 nm (E and F).

GP in the stromal connective tissues (Figures 2 and 3).
Epithelial cell positivity for EBOV by IHC in these organs was
rare. In the head and tail of the epididymis, histopathological
lesions secondary to EVD were nonspeciﬁc, but included
interstitial edema and, rarely, vascular thrombosis. Similar
widespread multifocal positivity for EBOV VP40 and GP was
detected in the interstitial connective tissue supporting the
tubular epithelium of the epididymis in acutely EVD-affected
macaques (Figure 3). Ultrastructural examination of the
prostate gland, epididymis, and seminal vesicle conﬁrmed viral
infection of interstitial mesenchymal cells, including endothelial cells (Figures 2 and 3). Mature EBOV particles were
seen within the disrupted membranes of an expanded endoplasmic reticulum; however, the virus was only observed to
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bud from the cell surface or plasma membrane. Ebola virus GP
is known to accumulate in the endoplasmic reticulum of
infected cells,18,19 which may partially explain the marked
expansion of endoplasmic reticulum membranes observed
occasionally in EBOV-infected cells. Within the ductus
deferens, epithelial positivity for EBOV VP40 protein was
observed (data not shown).

Discussion
Using the macaque model of acute EVD, we have demonstrated early and widespread infection of the male and
female reproductive tract after i.m. EBOV challenge. Ebola
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Figure 3 Epididymis (A, C, and E) and seminal
vesicle (B, D, and F). A: Section of epididymis
immunohistochemically (IHC) stained for Ebola
virus (EBOV) viral protein 40 (VP40) matrix protein, shows multifocal positive cytoplasmic staining (brown) of the interstitial mesenchymal cells
of the epididymis. B: Section of seminal vesicle
IHC stained for EBOV VP40 matrix protein shows
multifocal cytoplasmic positivity (brown) in the
mesenchymal cells of the seminal vesicle. C and E:
The black boxed area in A reveals the anatomical
orientation seen in transmission electron micrographs (TEMs). C: Four intracytoplasmic EBOV inclusion bodies are present within mesenchymal
cells adjacent to the basement membrane (BM) of
the epididymal epithelium (Ep). E: Higher magniﬁcation of the red boxed area in C. Filamentous
EBOV nucleocapsid proteins form an intracytoplasmic inclusion body in an interstitial
mesenchymal cell adjacent to the BM of the Ep. D
and F: The black boxed area in B represents the
anatomical orientation of the TEMs. D: An intracytoplasmic EBOV inclusion body is present in a
mesenchymal cell adjacent to the Ep of the seminal
vesicle. F: Higher magniﬁcation of the red boxed
area in D. An intracytoplasmic EBOV inclusion
body demonstrates EBOV nucleocapsid formation
in longitudinal and cross section [in cross section
appearing as crystalline arrays (CAs)] adjacent to
the cell nucleus (top left). Scale bars: 200 mm (A
and B); 2 mm (C and D); 500 nm (E and F).

virus replication occurs predominantly within the mesenchymal or supporting stromal cells of the reproductive tract.
The presence of the virus in the ovary and uterus in the
macaque model of EVD has not been reported previously.
However, detection of EBOV in the thecal mesenchymal
cells surrounding ovarian follicles and IHC positivity
associated with inﬂammation in necrosis in the uterus have
been demonstrated in the guinea pig model of EVD.20 The
effect of EBOV infection of thecal cells on the denouement
of secondary and tertiary ovarian follicles in macaques is
unknown. The effect of EBOV infection of smooth muscle
cells in the uterus is also unknown; however, in pregnant
women with EVD, an average maternal death rate of 82%
and a fetal death rate of 100% have been reported.21 Ebola
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virus is able to infect the fetus.22 In the placenta, fetal-origin
syncytiotrophoblasts can be infected with the Sudan and
Bundibugyo viruses.21 The only known congenitally infected infant to survive EBOV infection was treated on 2, 5, 8,
and 11 days of life with the monoclonal antibody cocktail,
ZMapp, and received an i.v. transfusion of leukocytes from
an EBOV survivor on day 11 of life; beginning on day 19 of
life, this infant was treated for 12 days with the nucleotide
analog prodrug, GS-5734.23 Ebola virus is shed in breast
milk, and epidemiologically linked transmission from an
asymptomatic mother to a 9-month-old child through breast
milk has been reported.24 The presence or absence of EBOV
persistence in women is understudied, as are the effects of
EVD in pregnant women and their offspring.
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In men, temporal evidence and sequence analysis of
EBOV samples from the 2014 to 2016 West Africa outbreak
demonstrated sexual transmission of EBOV to women from
6 months to >1 year after recovery from EVD.7,8 A recent
report from Fischer et al25 described the longest interval,
965 days, between onset of EVD and the detection of
EBOV RNA in semen. The prevalence of detection was
signiﬁcantly higher in older men (median age, 41.8 years),
and detection was intermittent. On the basis of our ﬁndings,
we hypothesize that persistence is established in the interstitial tissues of the reproductive tract and tissue macrophages are the route by which EBOV is transmitted from
stromal replication sites in the seminal vesicle, epididymis,
prostate gland, and testis into the seminal ﬂuid. Because this
study used tissue collected adjunctively at necropsy from
ongoing studies, the collection and examination of seminal
ﬂuid was not possible, and no fresh tissue was collected for
RNA sequencing.
Infection of monocytes and macrophages facilitates systemic spread of the EBOV but neutrophils and B, T, and
natural killer cells, critical for both the innate and humoral
immune response, are not infected.26 Although we have
demonstrated active EBOV infection of endothelial cells in
reproductive tissues, endothelial cells exhibit a high degree
of heterogeneity, and endothelial cell infection within one
tissue type likely does not translate to permissivity of viral
infection in another.27 Although the macaque model of
human EVD is thought to have a high ﬁdelity, it is unknown
if the distribution of the virus is similar in the reproductive
tract of affected humans or why sexual transmission in
convalescent human populations is rare. Martines et al28
reported positivity for EBOV antigens by IHC in testicular
endothelium and focally within the seminiferous tubular
cells in one man. Zeng et al29 recently reported detection of
EBOV viral RNA in the interstitial tissues of the testis and
epididymis, in the same pattern we describe herein, at day
43 after EBOV exposure in 1 of 76 nonhuman primate EVD
survivors after experimental countermeasure treatment.
These ﬁndings support the need for an established deﬁnition
of EBOV persistence in the macaque model of EVD and to
determine whether the presence of viral RNA in the semen
equates to the presence of infectious EBOV. The ﬁndings
from Fischer et al25 and Zeng et al29 also highlight the need
to evaluate multiple seminal samples from a diverse study
cohort for the presence of EBOV to determine whether age
affects the incidence of EBOV persistence. Proposed EVD
countermeasures need to be evaluated for efﬁcacy and to
determine whether they facilitate the development of EBOV
persistence.
Several RNA viruses that establish persistence in infected
hosts may provide valuable insight into EBOV persistence.30 Equine arteritis virus establishes persistent infection
in stallions after recovery from clinical disease. The stromal
cells of the ampulla, inﬁltrating tissue macrophages, T cells,
and B cells in stallions are persistently infected, in the
presence of neutralizing antibody.31 Persistence of equine
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arteritis virus is associated with polymorphisms in the
stallion’s CXCL16 gene. Virus shedding in seminal ﬂuid
continues for an average of 165 days after infection in the
absence of viremia and clinical evidence of reproductive
dysfunction. Although a genetic link associated with viral
persistence of EBOV in humans has yet to be established,
such a link might explain the rarity of seminal transmission
of EBOV.
Survival from EVD has been associated with an early and
robust CD8þ T-cell response.32 The presence of EBOV in
the stroma or interstitial tissues of the reproductive tract may
be one of several mechanisms by which the virus evades
early antiviral T-cell responses in immune-privileged sites to
facilitate the establishment of persistence. Up-regulation of
the ligand for the immune inhibitory receptor, programmed
cell death 1 (CD274) pathway, has been shown in immuneprivileged sites, such as the seminiferous tubules of the
testes in mice.33 This pathway is thought to be key in
modulating immune function through inhibition of
programmed cell death 1epositive CD8þ T lymphocytes.33,34 Resident tissue macrophages in the interstitium of
the testis exhibit an M2, or immunosuppressive, phenotype,
which may facilitate the development of viral persistence.35
The virus likely evades the immune system through several
mechanisms, including the production of two proteins,
VP24 and VP35, that inhibit the production of interferon a
in antigen-presenting cells, thus attenuating T-cell receptor
activation and T-cell expansion.36,37 During infection, the
virus down-regulates GP while concurrently releasing a
soluble GP that binds circulating neutralizing antibodies
directed against EBOV GP on cell surfaces.38 In vitro,
EBOV establishes noncytolytic persistent infections through
the production of defective interfering particles.39,40 A
nonhuman primate EBOV survival model would be required
to study the host immunomodulatory mechanisms that
facilitate the development of EBOV persistence in immuneprivileged sites and to determine how this highly pathogenic
virus attenuates itself to persist in host cells.
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